RAPT.Rapt Therapeutics, INC

SCHEDULE 13G: OrbiMed Advisors Discloses Significant Passive Stake in RAPT Therapeutics

Sentiment:

Beneficial Ownership Disclosure

📋All filings for Rapt Therapeutics, INC
🔒Login to Follow

OrbiMed Advisors LLC has reported a 9.9% passive ownership stake in RAPT Therapeutics, Inc., holding 13,135,260 shares as of December 31, 2024.

Summary

  • OrbiMed Advisors LLC, an investment adviser, has filed a Schedule 13G indicating beneficial ownership of 13,135,260 shares of Common Stock in RAPT Therapeutics, Inc.
  • This stake represents 9.9% of RAPT Therapeutics, Inc.'s outstanding common stock.
  • The filing indicates that OrbiMed Advisors LLC holds shared voting power and shared dispositive power over all 13,135,260 shares.
  • The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
  • The event date requiring this filing was December 31, 2024, with the statement filed on February 14, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a specialized healthcare investment firm like OrbiMed Advisors is generally viewed positively, indicating confidence in the issuer, RAPT Therapeutics, Inc.

Positives

  • The disclosure of a significant 9.9% stake by OrbiMed Advisors LLC, a reputable healthcare-focused investment firm, signals institutional confidence in RAPT Therapeutics, Inc.
  • OrbiMed's passive investment suggests a long-term view and belief in the company's underlying value without seeking to influence control.

Future Outlook

This Schedule 13G filing is a disclosure of past ownership and does not contain forward-looking statements or guidance from RAPT Therapeutics, Inc. or OrbiMed Advisors LLC regarding future performance or strategic direction.

Industry Context

OrbiMed Advisors is a prominent investment firm specializing in the healthcare sector, including biotechnology and pharmaceuticals. Their significant investment in RAPT Therapeutics, Inc., a company focused on immunology and oncology, aligns with OrbiMed's core investment strategy and indicates their assessment of RAPT's potential within the competitive biotech landscape.

Stakeholder Impact

  • Shareholders: The disclosure of a significant institutional investor's stake can enhance market confidence and potentially attract further institutional interest, positively impacting share price stability and liquidity.

Key Dates

DateDescription
12/31/2024Date of event which required the filing of this statement, indicating the beneficial ownership threshold was met or exceeded.
02/14/2025Date the Schedule 13G statement was signed and filed with the SEC.

Recommendation

hold

Keywords

RAPT Therapeutics, OrbiMed Advisors, Schedule 13G, SEC filing, institutional ownership, biotechnology, pharmaceuticals, investment adviser, passive investment, common stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.